KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Cost of Revenue: 2009-2025

Historic Cost of Revenue for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $107.4 million.

  • Neogenomics' Cost of Revenue rose 15.50% to $107.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.0 million, marking a year-over-year increase of 10.25%. This contributed to the annual value of $370.5 million for FY2024, which is 6.75% up from last year.
  • As of Q3 2025, Neogenomics' Cost of Revenue stood at $107.4 million, which was up 3.15% from $104.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Cost of Revenue registered a high of $107.4 million during Q3 2025, and its lowest value of $68.7 million during Q2 2021.
  • Over the past 3 years, Neogenomics' median Cost of Revenue value was $92.0 million (recorded in 2024), while the average stood at $93.1 million.
  • Data for Neogenomics' Cost of Revenue shows a peak YoY rose of 23.97% (in 2021) over the last 5 years.
  • Over the past 5 years, Neogenomics' Cost of Revenue (Quarterly) stood at $80.5 million in 2021, then climbed by 1.75% to $81.9 million in 2022, then increased by 7.43% to $88.0 million in 2023, then increased by 7.71% to $94.7 million in 2024, then climbed by 15.50% to $107.4 million in 2025.
  • Its Cost of Revenue was $107.4 million in Q3 2025, compared to $104.1 million in Q2 2025 and $94.8 million in Q1 2025.